

Radicava™ (edaravone)
Effective 11/26/18

Plan	<input checked="" type="checkbox"/> MassHealth <input checked="" type="checkbox"/> Commercial/Exchange	Program Type	<input checked="" type="checkbox"/> Prior Authorization
Benefit	<input type="checkbox"/> Pharmacy Benefit <input checked="" type="checkbox"/> Medical Benefit (NLX)		<input type="checkbox"/> Quantity Limit <input type="checkbox"/> Step Therapy
Specialty Limitations	N/A		
Contact Information	Specialty Medications		
	All Plans	Phone: 866-814-5506	Fax: 866-249-6155
	Non-Specialty Medications		
	MassHealth	Phone: 877-433-7643	Fax: 866-255-7569
	Commercial	Phone: 800-294-5979	Fax: 888-836-0730
	Exchange	Phone: 855-582-2022	Fax: 855-245-2134
	Medical Specialty Medications (NLX)		
	All Plans	Phone: 844-345-2803	Fax: 844-851-0882
Exceptions	N/A		

Overview

Radicava (edaravone) is indicated for the treatment of amyotrophic lateral sclerosis (ALS).

Coverage Guidelines

Authorization may be granted when all the following criteria have been met and documentation has been submitted:

1. Member as documented diagnosis of ALS based on EI Escorial revised criteria
2. Medication must be prescribed by a neurologist or physiatrist with expertise in the treatment of ALS.
3. Member is stable on Rilutek (riluzole) or the prescriber has submitted clinical rationale why Rilutek (riluzole) is not appropriate.
4. Member has normal respiratory function defined as percent-predicted forced vital capacity (FVC) values of $\geq 80\%$
5. Member has a score of at least 2 points on each individual item of the ALS Functional Rating Scale – Revised (ALSFRS-R)
6. Member has had duration of disease for 2 years or less
7. Member does not require noninvasive or invasive ventilatory support

Continuation of Therapy

Reauthorization may be granted for members when ALL the following criteria are met:

1. Medication is prescribed by a neurologist or physiatrist with expertise in the treatment of ALS.
2. Documentation confirming the patient has benefitted from Radicava (Edaravone) therapy as demonstrated by a slowing in the decline of functional abilities is submitted.

Limitations



1. Initial approvals will be granted for 6 months.
2. Reauthorizations will be granted for 12 months.

References

1. Radicava (edaravone) [prescribing information]. Jersey City, NJ: MT Pharma America Inc; May 2017.
2. Nagase M, Yamamoto Y, Miyazaki Y, Yoshino H. Increased oxidative stress in patients with amyotrophic lateral sclerosis and the effect of edaravone administration. *Redox Rep.* 2016;21(3):104-112.[PubMed 26191780]
3. Miller RG, Mitchell JD, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). *Cochrane Database Syst Rev* 2012: CD001447
4. [Study of functional rating scale for amyotrophic lateral sclerosis: revised ALSFRS(ALSFRS-R) Japanese version]. *No To Shinkei.* 2001 Apr;53(4):346-55.
5. Writing Group, Edaravone (MCI-186) ALS 19 Study Group. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. *Lancet Neurol* 2017; 16:505.
6. Hardiman O, van den Berg LH. Edaravone: a new treatment for ALS on the horizon? *Lancet Neurol* 2017; 16:490

Review History

11/26/18 – Reviewed

Disclaimer

AllWays Health Partners complies with applicable federal civil rights laws and does not discriminate or exclude people on the basis of race, color, national origin, age, disability, or sex.